Hercules Capital, Inc. (NYSE: HTGC) announced on March 26, 2025, that it has entered into a loan and security agreement with Savara Inc. for up to $200 million in non-dilutive debt financing. This capital aims to strengthen Savara's balance sheet following its Biologics License Application (BLA) submission for MOLBREEVI*.
Under the terms of the agreement, $30 million was funded at the execution of the agreement, which will be used to repay Savara's existing $26.5 million debt facility. An additional $100 million will become available upon FDA approval of MOLBREEVI and certain other milestones.
The loan agreement has a maturity of five years, with an initial 36-month interest-only period that can be extended to 60 months upon achieving FDA approval for MOLBREEVI. This financing underscores Hercules Capital's dedication to supporting novel and life-changing therapies in the biopharmaceutical market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.